BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, October 21, 2013
At least six biotechs and pharmas reported earnings
last week. Sales of new products helped big pharmas Johnson & Johnson
(NYSE:JNJ) and Roche (SIX:ROG; OTCQX:RHHBY) beat the Street's revenue
estimates. For instance, J&J reported a 73% increase in sales of Zytiga
abiraterone to $464 million in 3Q13. The drug was approved for metastatic
castration-resistant prostate cancer (CRPC) in the U.S. and EU in 2011. The
label was expanded to chemotherapy-naïve patients in the U.S. in 2012 and in
the EU earlier this year. J&J added $6.1 billion to its market cap last
week. In its 3Q13 update, Roche CEO Severin Schwan highlighted uptake of breast
cancer drugs Perjeta pertuzumab and Kadcyla ado-trastuzumab emtansine. Perjeta
sales in 3Q were CHF78 million ($86 million), while sales of Kadcyla were CHF73
million ($80 million). Perjeta was launched in the U.S. in 2012 and in the EU
in March, and Kadcyla was launched in the U.S. in February. Kadcyla uses
antibody-drug conjugate technology from ImmunoGen Inc. (NASDAQ:IMGN).
Roche added $2.8 billion to its market cap last week, while shares of
ImmunoGen were up 4% on the week. Abbott Laboratories (NYSE:ABT) tacked
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]